Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating swallowing disorders in intensive care unit patients who have tracheostomies and face difficulties weaning from mechanical ventilation. These disorders can lead to serious problems like respiratory complications and poor nutrition. The study aims to develop and test a new ultrasound-based diagnostic model to improve detection of swallowing difficulties, offering a less invasive alternative to current methods such as videofluoroscopy or Fiberoptic Endoscopic Evaluation of Swallowing FEES. This observational study will enroll 119 difficult-to-wean tracheostomised patients over a nineteen-month period at multiple hospitals. Each participant will undergo FEES and ultrasound evaluations within a two-hour timeframe. Ultrasound will assess movements and structures involved in swallowing, including the tongue, hyoid bone, and suprahyoid muscles. The ultrasound operator will be blinded to other patient information. The study will use logistic regression to create an ultrasound diagnostic score, which will be evaluated for its accuracy and reliability. Participants will have demographic and medical data collected alongside the swallowing assessments. Ultrasound measurements will be performed in a semi-recumbent position, focusing on muscle thickness, movement, and contraction. Reliability will be tested through repeated evaluations by different operators. The primary outcome is the development of the ultrasound prediction model on the day of FEES. Secondary outcomes include assessing the accuracy and reliability of tongue, hyoid, and muscle characteristics. The study includes ongoing monitoring and data recording during the enrollment period.
Actively Recruiting
Researchers are conducting a Phase III international trial to study the effects and safety of androgen deprivation therapy ADT with or without darolutamide in men newly diagnosed with metastatic prostate cancer who have vulnerable functional abilities. This study specifically includes patients who have not chosen treatment with docetaxel or other androgen receptor pathway inhibitors. The goal is to evaluate how these treatments impact disease progression and patient health over time. Participants will be randomly assigned to one of two groups one receiving ADT plus darolutamide 600 mg taken orally twice daily, and the other receiving ADT plus a placebo taken with the same schedule. Treatment will continue until imaging shows disease progression or until the patient or doctor decides to stop for reasons such as side effects or other health issues. After stopping treatment, patients will enter a follow-up phase lasting up to 10 years to monitor survival, further treatments, and any ongoing or new side effects. During the study, participants will undergo regular assessments including imaging scans to check for cancer progression, blood tests, evaluations of urinary symptoms, and quality of life questionnaires. Researchers will track outcomes like progression-free survival, overall survival, symptom changes, and adverse events. Monitoring visits will occur periodically both during treatment and follow-up to gather comprehensive data on health status and treatment effects.
Actively Recruiting
Radiotherapy for breast cancer can cause arm lymphedema, which is swelling that may lead to long-term discomfort and affect quality of life. This clinical trial is designed to assess whether an artificial intelligence AI tool that predicts individual risk of arm lymphedema after radiotherapy can help patients and doctors make better treatment decisions. The trial includes women aged 18 or older with breast cancer needing regional lymph node radiotherapy after surgery, regardless of hormone receptor or tumor status. Participants will be randomly assigned to two groups. In the experimental group, patients and physicians will see the AI-predicted risk through a web app that explains risk factors and suggests measures like compression sleeves. In the control group, this risk information will not be shared. Both groups receive the same radiotherapy treatment they would normally have, with no changes to dose or technique. The AI tool is evaluated only for its impact on decision-making and outcomes. Throughout two years, participants will have regular check-ups to track treatment choices, side effects, shoulder movement, breast appearance, quality of life, and the accuracy of the AI tools predictions. Researchers will also monitor how well patients follow recommendations for using compression sleeves, as well as cancer recurrence and survival. Questionnaires and clinical exams will be conducted at baseline, during treatment, and at multiple follow-up points to gather detailed information.
Actively Recruiting
Researchers are investigating treatments for patients with hormone receptor-positive, HER2 low or ultralow metastatic breast cancer who are undergoing first-line therapy with a CDK46 inhibitor combined with an aromatase inhibitor or fulvestrant. This open-label, multicenter phase II study focuses on patients whose tumor DNA remains detectable in their blood after four weeks of standard therapy, aiming to evaluate progression-free survival using trastuzumab deruxtecan T-DXd treatment. Patients first enter a screening phase to confirm the presence of circulating tumor DNA after starting standard treatment. Those with persistent tumor DNA are enrolled in the treatment phase, where they receive trastuzumab deruxtecan as an intravenous injection every three weeks at a dose of 5.4 mgkg. This single-group study evaluates how long patients live without disease progression while receiving the study drug. Participants undergo regular assessments including laboratory tests and imaging to monitor their disease status and safety during the study. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, clinical benefit, time to response, and treatment toxicity up to five years. Participants are followed for outcomes and safety throughout the study period, which may last several years.
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effects of American ginseng combined with vitamin C from Camu Camu berries on fatigue in patients treated for localized breast or gynecological cancer. This multicenter randomized trial aims to assess the safety and efficacy of the dietary supplement Qiseng in improving cancer-related fatigue. The study is randomized, double-blind, and placebo-controlled, led by the Centre Francois Baclesse. Participants receive either Qiseng, containing 200 mg of P. quinquefolius extract 30 mg ginsenosides plus 30 mg vitamin C, or a placebo made of microgranules without active extracts. Both groups take 2 capsules daily for 8 weeks. The trial includes detailed monitoring of fatigue and other quality-of-life aspects during and after treatment. During the study, participants will have their fatigue levels assessed after 1 week and 4 weeks following the 8-week treatment. Researchers will also evaluate other fatigue dimensions, treatment-related side effects, quality of life, anxiety, cognitive function, physical activity, sleep quality, and treatment acceptability at multiple timepoints. The study spans approximately 12 weeks with close follow-up for safety and outcome measurement.
Actively Recruiting
Researchers are evaluating Tislelizumab as a first-line treatment for elderly patients aged 70 and above who have advanced esophageal squamous-cell carcinoma ESCC and are not eligible for platinum-based chemotherapy. This phase II, open-label study aims to assess the safety of Tislelizumab and its impact on overall survival at 6 months, considering PD-L1 protein expression on immune cells, along with other outcomes such as response rates, progression-free survival, quality of life, and immune biomarker prognostics. Participants will receive Tislelizumab, a monoclonal antibody targeting PD-1, administered by intravenous infusion at a dose of 200 mg every 3 weeks. Treatment will continue until disease progression or unacceptable toxicity occurs, for a maximum duration of 2 years. Patients will be included regardless of PD-L1 status, with central comparisons made as part of ancillary analyses. During the study, participants will undergo regular assessments including imaging to evaluate tumor response, questionnaires to assess health-related quality of life, and geriatric evaluations. Safety will be monitored up to 90 days after the last dose. Researchers will measure overall survival at 6 months as the primary outcome, alongside secondary measures such as progression-free survival at 3 and 6 months, immune biomarker analysis, and comprehensive health evaluations throughout the treatment period and follow-up visits.
Actively Recruiting
Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.
Actively Recruiting
Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.
Actively Recruiting
Researchers are conducting a French national observational study to evaluate patients with HER2-negative early breast cancer who are treated with olaparib. The study aims to understand how many patients complete the full adjuvant olaparib treatment in a real-world setting. This study observes patients receiving olaparib as part of their standard care without assigning treatments. Participants are those diagnosed with HER2-negative early breast cancer and starting adjuvant olaparib based on their physicians decision. The study does not provide or assign treatments but follows patients who are prescribed olaparib in routine clinical practice. There are no comparison groups or placebo treatments in this observational study. During the study, researchers will monitor patients for up to 18 months to measure the proportion who complete the full olaparib treatment course. They will also collect information on BRCA mutation characteristics, medical history, and the timing of treatment discontinuation. Participants will be observed through routine care without additional interventions, allowing researchers to assess real-world treatment adherence and outcomes.
1-10 of 13
1